


4-7-03



PATENT
Docket No. 1400-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

WILLIAM J. ROBERTS

Entitled: "BIOAVAILABLE PRODRUGS OF
ANDROGENIC STEROIDS AND RELATED
METHOD"

Serial No.: 09/872,705

Filed: June 1, 2001

Group Art Unit: 1616

Examiner: Qazi, Sabiha Naim

TECH CENTER 1600/2900

APR 09 2003

RECEIVED

Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97(c) to bring to the attention of the Examiner the documents listed on the attached Form PTO/SB/08A. It is being filed after the occurrence of events identified in § 1.97(b), but upon information and belief before the mailing date of either a final office action or a notice of allowance. Copies of the listed documents are attached.

Applicant also brings to the attention of the Examiner the following co-pending applications, a copy of each of which is attached:

1. Serial No. 10/053,345 to Roberts (Attorney Docket No. 1400-003);
2. Serial No. 10/053,505 to Roberts (Attorney Docket No. 1400-004); and

04/08/2003 09:00:00 09872705 180.00 DP
01 FC:1806

3. Serial No. 10/265,218 to Roberts (Attorney Docket No. 1400-063).

Please initial this Information Disclosure Statement next to each of the above-listed co-pending applications, and return a copy of the initialed IDS to Applicant with the next written communication.


The fee set forth in 37 C.F.R. § 1.17(p) required by 37 C.F.R. § 1.97(c) in lieu of certification is filed herewith. Should that fee be deficient, please charge the deficiency to our Deposit Account 501324 under Order No. 1400-002.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that any or all of the listed documents are material or constitute "prior art." Applicant reserves the right to challenge the characterization of any of these documents or information as "prior art." Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Consideration of the foregoing and enclosures plus return of a copy of the herewith Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly requested.

Dated: April 3, 2003

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Sarah L. Malcolm", with a stylized flourish at the end.

Sarah L. Malcolm
Reg. No. 53,259

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 09/872,705 |
| Filing Date | June 1, 2001 |
| First Named Inventor | William J. Roberts |
| Group Art Unit | 1616 |
| Examiner Name | Qazi, Sabiha Naim |
| Attorney Docket Number | 1400-002 |

| U.S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | | US-2,843,608 | 07-15-1958 | Colton | |
| | | US- 3,056,727 | 10-02-1962 | Allais et al. | |
| | | US- 3,314,856 | 04-18-1967 | Allais et al. | |
| | | US- 3,433,813 | 03-18-1969 | Boswell | |
| | | US- 3,435,030 | 03-25-1969 | Klimstra | |
| | | US- 3,481,957 | 12-02-1969 | Cross et al. | |
| | | US- 3,523,126 | 08-04-1970 | Boswell | |
| | | US- 4,087,524 | 05-02-1978 | Grunwell et al. | |
| | | US- 4,239,681 | 12-16-1980 | Grunwell et al. | |
| | | US- 5,053,403 | 10-01-1991 | Orentreich et al. | |
| | | US- 5,387,583 | 02-07-1995 | Loria | |
| | | US- 5,391,776 | 02-21-1995 | Ueno et al. | |
| | | US- 5,578,588 | 11-26-1996 | Mattern et al. | |
| | | US- 5,880,117 | 03-09-1999 | Arnold | |
| | | US- 6,011,027 | 01-04-2000 | Arnold | |
| | | US- 6,017,964 | 01-25-2000 | MacLean et al. | |
| | | US- 6,117,429 | 09-12-2000 | Bucci | |
| | | US- 2001/0041698 A1 | 11-15-2001 | Arnold | |
| | | US- 2001/0056087 A1 | 12-27-2001 | Arnold | |
| | | US- 2002/0183532 A1 | 12-05-2002 | Roberts | |

[illegible]

Examiner
Signature


Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|----|---|--------------------------|--------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/872,705 |
| | | | | Filing Date | June 1, 2001 |
| | | | | First Named Inventor | William J. Roberts |
| | | | | Group Art Unit | 1616 |
| | | | | Examiner Name | Qazi, Sabiha Naim |
| Sheet | 2 | of | 2 | Attorney Docket Number | 1400-002 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|--------------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | BLAQUIER et al., "In Vitro Metabolism of Androgens in Whole Human Blood", Acta Endocrinologica, May-August 1967, 697-704, Vol. 55, Periodica, Copenhagen. | |
| | | EARNEST et al., "In Vivo 4-androstene-3,17-dione and 4-androstene-3 β ,17 β -diol Supplementation in Young Men", European Journal of Applied Physiology, February 2000, 229-232, Vol. 81, No. 3, Springer, New York. | |
| | | FRANKE et al., "Hormonal Doping and Androgenization of Athletes: A Secret Program of the German Democratic Republic Government", Clinical Chemistry, Nov. 7, 1997, 1262-1279, Vol. 43, No. 7, American Association for Clinical Chemistry, United States of America. | |
| | | INABA et al., "Conversion of 4-Androstenediol and 5-Androstenediol to Testosterone, and Conversion of Dehydroepiandrosterone to 4-Androstenediol by Rat Testis In Vitro", Endocrinol. June 1966, 160-172, Vol. 13, No. 2, Japan. | |
| | | URALETS et al., "Over-the-Counter Anabolic Steroids 4-Androsten-3, 17-dione; 4-Androsten-3 β ,17 β -diol; and 19-nor-4-Androsten-3, 17-dione: Excretion Studies in Men", Journal of Analytical Toxicology, September 1999, 357-366, Vol. 23, : Preston Publications, Niles, Illinois. | |
| | | YAMAJI et al., "Androstenediol in Canine Spermatid Vein Blood and Its Significance in Testosterone Biosynthesis in Vivo". Endocrinology, 1968, 992-998, Vol. 83, J. B. Lippincott, Philadelphia. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.